NCT01395004 - A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions

Langerhans Cell Histiocytosis

Interventions

DRUG

GSK2110183

GSK2110183 was orally administered at 125 mg once daily.

Trial Locations (5)

Memorial Sloan Kettering Cancer Center, New York

Staten Island University Hospital, Staten Island

Johns Hopkins Hospital, Baltimore

Baylor College of Medicine, Houston

Dana Farber Cancer Institute, Boston